Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RISANKIZUMAB vs RISPERDAL CONSTA: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RISANKIZUMAB vs RISPERDAL CONSTA: Safety Overview

Metric RISANKIZUMAB RISPERDAL CONSTA
Total FAERS Reports 2,642 140
Deaths Reported 41 29
Death Rate 1.6% 20.7%
Hospitalizations 439 56
Average Patient Age 52.1 yrs 45.0 yrs
% Female Patients 51.3% N/A
Manufacturer AbbVie Inc. N/A
Route SUBCUTANEOUS N/A